Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Determining eligibility for autologous hematopoietic cell transplantation

Leona A Holmberg, MD, PhD
H Joachim Deeg, MD
Brenda M Sandmaier, MD
Section Editor
Nelson J Chao, MD
Deputy Editor
Alan G Rosmarin, MD


Hematopoietic cell transplantation (HCT) refers to the administration of hematopoietic progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood) or donor (eg, allogeneic, autologous) to reconstitute the bone marrow. Autologous HCT (auto-HCT) uses hematopoietic progenitor cells derived from the individual with the disorder and is used increasingly to treat a variety of hematologic neoplasms.

Eligibility for auto-HCT varies across countries and institutions. Ultimately, decisions regarding transplant eligibility should be made on a case by case basis based on a risk-benefit assessment, and the needs and wishes of the patient. This topic will discuss eligibility for auto-HCT. Eligibility for allogeneic HCT, the use of HCT in specific disease settings, and the short and long term complications of HCT are discussed separately. (See "Determining eligibility for allogeneic hematopoietic cell transplantation" and "Management of the hematopoietic cell transplant recipient in the immediate post-transplant period" and "The approach to hematopoietic cell transplantation survivorship".)


Autologous hematopoietic cell transplantation (auto-HCT) is most commonly performed for the management of patients with multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. There are no accepted guidelines regarding indications for auto-HCT and recommendations regarding indications for auto-HCT differ between transplant centers [1]. The role of auto-HCT in specific diseases is discussed in more detail separately. In general, auto-HCT may be considered in the following settings:

Multiple myeloma – As consolidation therapy following initial response to chemotherapy or for the treatment of relapsed or refractory disease. (See "Overview of the management of multiple myeloma", section on 'Autologous HCT versus chemotherapy alone' and "Autologous hematopoietic cell transplantation in multiple myeloma".)

Hodgkin lymphoma – Treatment of chemotherapy-sensitive relapsed disease. (See "Hematopoietic cell transplantation in classical Hodgkin lymphoma" and "Treatment of relapsed or refractory classical Hodgkin lymphoma", section on 'Hematopoietic cell transplantation (HCT)'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 05, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Lee SJ, Joffe S, Artz AS, et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008; 26:2162.
  2. Maziarz R, Zhang MJ, Wang A, et al. CNS remission at the time of autologous stem cell transplantation improves outcome for patients with non-Hodgkin’s lymphoma with pre-existing CNS involvement: a CIBMTR analysis (abstract). Blood 2010; 116:abstract 371.
  3. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25:1993.
  4. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114:600.
  5. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93:51.
  6. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008; 83:614.
  7. Sharma M, Zhang MJ, Zhong X, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant 2014; 20:1796.
  8. Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 2012; 87:433.
  9. Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma 2015; 56:2379.
  10. Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014; 20:684.
  11. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.
  12. Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134:385.
  13. Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33:823.
  14. Ho VT, Weller E, Lee SJ, et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:223.
  15. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest 1992; 101:1257.
  16. Matute-Bello G, McDonald GD, Hinds MS, et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21:1125.
  17. Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 2009; 15:447.
  18. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118:6023.
  19. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24:853.
  20. Zver S, Zadnik V, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008; 88:227.
  21. Chung T, Lim WC, Sy R, et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart 2008; 94:911.
  22. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255.
  23. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114:1306.
  24. Majhail NS, Nayyar S, Santibañez ME, et al. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant 2012; 47:1385.
  25. Hari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010; 16:395.
  26. Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:231.
  27. Khaled Y, Abidi MH, Janakiraman N, et al. Outcomes after auto-SCT in African Americans with multiple myeloma. Bone Marrow Transplant 2009; 43:845.
  28. Verma PS, Howard RS, Weiss BM. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol 2008; 83:355.
  29. Saraf S, Chen YH, Dobogai LC, et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant 2006; 37:1099.
  30. Ford PA, Grant SJ, Mick R, Keck G. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. J Clin Oncol 2015; 33:1674.
  31. Vogl DT, Wang T, Pérez WS, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011; 17:1765.
  32. Costa LJ, Micallef IN, Inwards DJ, et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol 2008; 143:268.
  33. Labonté L, Iqbal T, Zaidi MA, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14:1039.
  34. Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014; 20:402.